In the article by Kempton et al, 1 couple of errors were identified.
Reference 14 was listed incorrectly. The correct reference has been mentioned below.
Theodore‐Oklota C, Humphrey L, Wiesner C, Schnetzler G, Hudgens S, Campbell A. Validation of a treatment satisfaction questionnaire in non‐Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. Patient Prefer Adherence. 2016;10:1767–1776.
The expansion of RASQ was mentioned as “Rituximab Administration Symptom Questionnaire”; however, the correct expansion is “Rituximab Administration Satisfaction Questionnaire”.
REFERENCE
- 1. Kempton C, Trask P, Parnes A, et al. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021;27:221‐228. [DOI] [PMC free article] [PubMed] [Google Scholar]